ASCO 2022 - Meeting Highlights-ASCO 2022 Meeting Highlights Webinar

Video Transcription

Video Summary

Today's webinar featured discussions on meeting highlights from the treatment of lung cancer from ASCO 2022. Dr. Antoinette Wozniak and Dr. Karen Reckamp presented on various topics including neoadjuvant therapy, immunotherapy, targeted therapy for EGFR mutations, and small cell lung cancer. Highlights from the webinar include the NATEM2 trial which showed a significant improvement in pathologic complete response with the addition of nevula-mab to chemotherapy in resectable stage 3 lung cancer. Analysis of multiple trials showed that the combination of chemotherapy and immunotherapy may have better outcomes compared to immunotherapy alone in patients with PD-L1 expression greater than 50%. The Skyscraper 2 study evaluated the addition of turigolumab, a TIGIT inhibitor, to standard chemotherapy and immunotherapy in extensive stage small cell lung cancer but did not show a significant improvement in progression-free or overall survival. The webinar also discussed targeted therapies for EGFR exon 20 insertion mutations and the importance of selecting the right treatment based on individual patient characteristics. Overall, the webinar provided valuable insights into the latest advancements in lung cancer treatment and highlighted the importance of personalized medicine in improving patient outcomes.

Meta Tag

Concept Early-Stage Non-Small Cell Lung Cancer

Concept Targeted Therapy

Concept KRAS G12C Mutation

Concept EGFR

Concept MET Exon 14 Skipping

Concept Exon 20 Insertion

Concept Amivantamab

Keywords

webinar

lung cancer

ASCO 2022

neoadjuvant therapy

immunotherapy

EGFR mutations

small cell lung cancer

chemotherapy

personalized medicine

Early-Stage Non-Small Cell Lung Cancer

Targeted Therapy

KRAS G12C Mutation

EGFR

MET Exon 14 Skipping

Exon 20 Insertion

Amivantamab